Citations (15)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Stephen J. Demarest, Kandasamy Hariharan & Jianying Dong. (2011) Emerging antibody combinations in oncology. mAbs 3:4, pages 338-351.
Read now
Read now
Stephen Hiscox, Peter Barrett-Lee & Robert I Nicholson. (2011) Therapeutic targeting of tumor–stroma interactions. Expert Opinion on Therapeutic Targets 15:5, pages 609-621.
Read now
Read now
Articles from other publishers (13)
Fangfang Liu, Qiong Wu, Zigang Dong & Kangdong Liu. (2023) Integrins in cancer: Emerging mechanisms and therapeutic opportunities. Pharmacology & Therapeutics 247, pages 108458.
Crossref
Crossref
Mustafa Kemal Ruhi, Brittany P. Rickard, William J. Polacheck & Imran Rizvi. 2023. Recent Advances, New Perspectives and Applications in the Treatment of Ovarian Cancer. Recent Advances, New Perspectives and Applications in the Treatment of Ovarian Cancer.
Ding Li & Stacey D. Finley. (2019) Exploring the Extracellular Regulation of the Tumor Angiogenic Interaction Network Using a Systems Biology Model. Frontiers in Physiology 10.
Crossref
Crossref
Takahiro Koyanagi, Yasuhiro Suzuki, Kazuki Komori, Yasushi Saga, Shigeki Matsubara, Hiroyuki Fujiwara & Yasufumi Sato. (2017) Targeting human vasohibin-2 by a neutralizing monoclonal antibody for anti-cancer treatment. Cancer Science 108:3, pages 512-519.
Crossref
Crossref
Andrea Sartori, Elisabetta Portioli, Lucia Battistini, Lido Calorini, Alberto Pupi, Federica Vacondio, Daniela Arosio, Francesca Bianchini & Franca Zanardi. (2016)
Synthesis of Novel c(AmpRGD)–Sunitinib Dual Conjugates as Molecular Tools Targeting the α
v
β
3
Integrin/VEGFR2 Couple and Impairing Tumor-Associated Angiogenesis
. Journal of Medicinal Chemistry 60:1, pages 248-262.
Crossref
Crossref
Yan Huang, Lenard M. Lichtenberger, Morgan Taylor, Justin N. Bottsford-Miller, Monika Haemmerle, Michael J. Wagner, Yasmin Lyons, Sunila Pradeep, Wei Hu, Rebecca A. Previs, Jean M. Hansen, Dexing Fang, Piotr L. Dorniak, Justyna Filant, Elizabeth J. Dial, Fangrong Shen, Hiroto Hatakeyama & Anil K. Sood. (2016) Antitumor and Antiangiogenic Effects of Aspirin-PC in Ovarian Cancer. Molecular Cancer Therapeutics 15:12, pages 2894-2904.
Crossref
Crossref
Francesca Roggiani, Delia Mezzanzanica, Katia Rea & Antonella Tomassetti. (2016) Guidance of Signaling Activations by Cadherins and Integrins in Epithelial Ovarian Cancer Cells. International Journal of Molecular Sciences 17:9, pages 1387.
Crossref
Crossref
Alessandra Monaco, Olivier Michelin, John Prior, Curzio Rüegg, Leonardo Scapozza & Yann Seimbille. (2014)
Synthesis of a non-peptidic PET tracer designed for
α
5
β
1
integrin receptor
. Journal of Labelled Compounds and Radiopharmaceuticals 57:5, pages 365-370.
Crossref
Crossref
Shen Hong, Han Haibing, Hu Jialiang, Zhang Xiaojuan, Wang Jingjing, Wang Wenjing, Nie Caihui & Xu Hanmei. (2014) PEGylated HM-3 presents anti-rheumatic bioactivity by inhibiting angiogenesis and inflammation. J. Mater. Chem. B 2:7, pages 800-813.
Crossref
Crossref
Sharath Gangadhara, Peter Barrett-Lee, Robert I Nicholson & Stephen Hiscox. (2012) Pro-metastatic tumor–stroma interactions in breast cancer. Future Oncology 8:11, pages 1427-1442.
Crossref
Crossref
Giovanni A. Infusino & Jeffrey R. Jacobson. (2012) Endothelial FAK as a therapeutic target in disease. Microvascular Research 83:1, pages 89-96.
Crossref
Crossref
Niv Papo, Adam P. Silverman, Jennifer L. Lahti & Jennifer R. Cochran. (2011)
Antagonistic VEGF variants engineered to simultaneously bind to and inhibit VEGFR2 and
α
v
β
3
integrin
. Proceedings of the National Academy of Sciences 108:34, pages 14067-14072.
Crossref
Crossref
Amir Abdollahi & Judah Folkman. (2010) Evading tumor evasion: Current concepts and perspectives of anti-angiogenic cancer therapy. Drug Resistance Updates 13:1-2, pages 16-28.
Crossref
Crossref